SCHEMBL24136591

SCHEMBL24136591

Cc1c(O)c(O)cc2c1C(=O)NCC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 10/20 0.42
▸ PARP1 P09874 7/20 0.42
▸ PARP11 Q9NR21 6/20 0.42
▸ ACHE P22303 2/20 0.42
▸ ADCY6 O43306 1/20 0.37
▸ ADCY3 O60266 1/20 0.37
▸ ADCY9 O60503 1/20 0.37
▸ ADCY5 O95622 1/20 0.37
▸ ADCY8 P40145 1/20 0.37
▸ ADCY7 P51828 1/20 0.37
▸ ADCY2 Q08462 1/20 0.37
▸ ADCY1 Q08828 1/20 0.37
▸ ADCY4 Q8NFM4 1/20 0.37
▸ GRM5 P41594 2/20 0.37
▸ HSP90AA1 P07900 1/20 0.36
▸ HSP90AB1 P08238 1/20 0.36
▸ CDC7 O00311 1/20 0.36
▸ PDPK1 O15530 1/20 0.36
▸ F7 P08709 1/20 0.36
▸ F3 P13726 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30466437 1.00 PARP10 (0.42) PARP10PARP1PARP11ACHEADCY6
SCHEMBL24136746 0.81 MAOA (0.39) PARP10PARP1PARP11ACHEGRM5
SCHEMBL14854360 0.80 PARP10 (0.42) PARP10PARP1PARP11ACHEADCY6
SCHEMBL24136723 0.77 ACHE (0.54) PARP10PARP1PARP11ACHE
SCHEMBL31012419 0.77 ACHE (0.54) PARP10PARP1PARP11ACHE
SCHEMBL24136677 0.75 ACHE (0.43) PARP10PARP1PARP11ACHECDC7
SCHEMBL30466416 0.75 ACHE (0.43) PARP10PARP1PARP11ACHECDC7
SCHEMBL24681239 0.75 PARP10 (0.44) PARP10PARP1PARP11ACHEADCY6
SCHEMBL22713749 0.71 PARP10 (0.47) PARP10PARP1PARP11ACHEADCY6
SCHEMBL22713717 0.71 PARP10 (0.44) PARP10PARP1PARP11ACHEGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11535629-B2 Dioxoloisoquinolinone derivatives and use thereof HANMI PHARMACEUTICAL CO., LTD. (KR) 2022-12-27 — — US disclosed
US-20220135582-A1 NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME HANMI PHARMACEUTICAL CO., LTD. (KR) 2022-05-05 — — US disclosed
EP-3929199-A1 NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME Hanmi Pharmaceutical Co., Ltd. (KR) 2021-12-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11535629-B2 Dioxoloisoquinolinone derivatives and use thereof EZH2, EZH1, EED PARP10 870/4885PARP1 1387/4885PARP11 1087/4885
US-20220135582-A1 NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME EZH2, EZH1, BMI1 PARP10 499/4885PARP1 1497/4885PARP11 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback